| Nov 7 |
Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million
|
| Oct 23 |
Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel
|
| Oct 22 |
Celularity Provides Corporate Update
|
| Oct 21 |
Celularity receives Nasdaq notice, intends to file appeal
|
| Oct 18 |
Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal
|
| Oct 16 |
Celularity acquires Rebound product from Sequence Lifescience
|
| Oct 16 |
Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.
|
| Sep 5 |
Celularity to Present at H.C. Wainwright’s 26th Annual Global Investment Conference
|
| Aug 28 |
Celularity Appoints Richard J. Berman to its Board of Directors
|
| Aug 23 |
Celularity receives Nasdaq notice regarding late Form 10-Q filing
|
